Core Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Core Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,635	Closed	-$59.9K	–	186
2025 Q4	$59.9K	Buy	14,635 +1,000	+7%	+$4.95K	0.03%	172
2025 Q3	$66.5K	Hold	13,635	–	–	0.03%	178
2025 Q2	$69K	Buy	13,635 +572	+4%	+$2.81K	0.04%	171
2025 Q1	$69.1K	Buy	+13,063	New	+$95.2K	0.04%	162

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Core Wealth Partners's RXRX Position: Q1 2026 in Review

Core Wealth Partners sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 14,635 shares — an estimated $59.9K sold.

Core Wealth Partners first reported a position in RXRX in Q1 2025 and held it in 4 quarters. The position peaked at $69.1K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Core Wealth Partners reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Core Wealth Partners sold 14,635 Recursion Pharmaceuticals shares in Q1 2026, an estimated $59.9K.
Core Wealth Partners first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Core Wealth Partners's Recursion Pharmaceuticals position peaked at $69.1K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Core Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.